Christopher S. Henney - Jun 25, 2021 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role
Director
Signature
/s/ Karin L. Walker, as Attorney in Fact for Christopher Henney
Stock symbol
PRTA
Transactions as of
Jun 25, 2021
Transactions value $
-$375,659
Form type
4
Date filed
6/29/2021, 06:13 PM
Previous filing
Jun 17, 2021
Next filing
Jul 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTA Ordinary Shares, par value $0.01 per share Options Exercise $197K +12K $16.43 12K Jun 25, 2021 Direct
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$488K -10.3K -85.53% $47.57 1.74K Jun 25, 2021 Direct F1
transaction PRTA Ordinary Shares, par value $0.01 per share Sale -$84.6K -1.74K -100% $48.73 0 Jun 25, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRTA Stock Option (Right to Buy) Options Exercise $0 +12K $0.00* 0 Jun 25, 2021 Ordinary Shares 12K $16.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades in prices ranging from $47.18 to $48.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2 The transaction was executed in multiple trades in prices ranging from $48.23 to $49.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The shares subject to the option were fully vested as of the date of the exercise.